切換帳號

  • FAQ
    • 新手指南
    • FAQ常見問題
  • 學術會議
  • 影音網
  • 登入

全站搜尋

台灣泌尿科醫學會E-School
  • 登入
  • FAQ
    • 新手指南
    • FAQ常見問題
  • 學術會議
  • 影音網
  • 到官網
  • Home
  • 到官網
  • Home
知識庫
  • 目錄總覽
  • 文件總覽
  • 最新討論
目錄 / 資料夾
  • 學術活動與演講
    • 年會
      • 2026半年會
        • 摘要
      • 2025年會 (UAA)
        • 摘要
      • 2025半年會
        • 摘要
      • 2024年會
        • 摘要
      • 2024半年會
        • 摘要
      • 2023年會
        • 摘要
      • 2023半年會
        • 摘要
      • 2022年會
        • 摘要
      • 2021年會
        • 摘要
      • 2021半年會
        • 摘要
      • 2020年會
        • 摘要
      • 2020半年會
        • 摘要
      • 2019年會
        • 摘要
      • 2019半年會
        • 摘要
      • 2018年會
        • 摘要
      • 2018半年會
        • 摘要
      • 2017年會
        • 摘要
      • 2017半年會
        • 摘要
      • 2016年會
        • 摘要
      • 2016半年會
        • 摘要
      • 2015年會
        • 摘要
  • 新手指南與FAQ
  1. 知識庫
  2. 最新上傳

最新上傳
(
  • 熱門
)

最新上傳

(
  • 熱門
)
(MP3-07) Comparison of Standard Transurethral Resection of Bladder Tumor and Laser En-bloc Resection of Bladder Tumor: A Single-centered Experience from Taipei Municipal Wanfang Hospital
2023-07-05
(MP3-06) Real-world outcome of endoscopic laser ablation for upper urinary tract urothelial carcinoma
2023-07-05
(MP3-05) High Incidence of Upgrading between Ureterorenoscopic Biopsy and Final Pathology in Upper Tract Urothelial Carcinoma: A Single Regional Hospital Experience
2023-07-05
(MP3-04) Survival outcomes of non-muscle invasive bladder urothelial carcinoma patients stratified by the updated EAU risk groups: Asian cohort
2023-07-05
(MP3-03) The study on the effects of Pterostilbene to cell apoptosis of bladder cancer cells
2023-07-05
(MP3-02) The Role of Capsaicin in Inhibiting Bladder Tumor Metastasis through the Regulation of Matrix Metalloproteinase-11 Expression
2023-07-05
(MP3-01) The outcome of neoadjuvant immunotherapy for muscle-invasive urinary bladder urothelial carcinoma: single-center experience
2023-07-05
(MP2-10) SHARED DECISION-MAKING FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA—A REGIONAL TEACHING HOSPITAL EXPERIENCE
2023-07-05
(MP2-09) Endoureterotomy for Ureteral Stricture: A Retrospective Study of Holmium Versus Thulium Lasers
2023-07-05
(MP2-08) Comparison of Holding Strength on ligation Clips with Various Suture Types
2023-07-05
(MP2-07) Clinical Results of Overnight Catheterization in Patients with Neurogenic Bladder
2023-07-05
(MP2-06) Bladder capacity and urinary frequency in children
2023-07-05
(MP2-05) The Predictive Factors of Common Early Complications Following Transurethral Resection of the Prostate
2023-07-05
(MP2-04) Age- and gender-specific normal post void residual urine volume in healthy adolescents
2023-07-05
(MP2-03) Deep drop: a common finding in uroflowmetry of healthy children and adolescents
2023-07-05
(MP2-02) Artificial urinary sphincters in the treatment of post-prostatectomy incontinence: A summary of 22 years of experience from 4 medical institutions
2023-07-05
(MP2-01) Comparison of Thulium Laser Enucleation and Conventional transurethral resection among BPH patients: Single center study of functional outcome
2023-07-05
(MP1-10) Progression-Free Survival Following Stereotactic Body Radiotherapy for Bone Oligometastasis in Prostate Cancer and the Effect of Different Doses: A Single-Urologist, Single-Institute Experience
2023-07-05
(MP1-09) Molecular Expression Differences between Epithelioid and Sporadic Renal Angiomyolipoma: The Role of PTEN Loss and mTOR Pathway Activation
2023-07-05
(MP1-08) The long-term survival outcome of radical prostatectomy for localized prostate cancer with positive lymph node
2023-07-05
(MP1-07) The Impact of F18-Fluciclovine Positron Emission Tomography on Prostate Cancer Managements and Outcomes After Changing Managements
2023-07-05
(MP1-06) Public Chinese Prostate Cancer Professional Series-2:Updated Treatment for Clinically Localized/Regional Lymph Node Invasion Prostate Cancer (translated from NCCN Prostate Cancer Guidelines 2023 V1)
2023-07-05
(MP1-05) Public Chinese Prostate Cancer Professional Series-3:Updated Treatment for non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) (translated from NCCN Prostate Cancer Guidelines 2023 V1)
2023-07-05
(MP1-04) Public Chinese Prostate Cancer Professional Series-1:Accurate Diagnosis of Prostate Cancer (translated from NCCN Prostate Cancer Guidelines 2023 V1)
2023-07-05
  • <
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • >
/ 155
地址:台北市 11051 信義區基隆路一段432號6樓之1, 電話:02-2729-0819, 傳真:02-2729-0864
網址: http://eschool.tua.org.tw,  EMail: eschool@tua.org.tw